{
    "symbol": "SGEN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-27 21:30:29",
    "content": "  Speakers on today\u00e2\u0080\u0099s call will be Roger Dansey, Interim Chief Executive Officer and Chief Medical Officer; Todd Simpson, Chief Financial Officer; and Chip Romp, Executive Vice President, Commercial U.S. Today\u00e2\u0080\u0099s conference call will include forward-looking statements regarding future or anticipated events and results, including the company\u00e2\u0080\u0099s 2022 financial outlook, anticipated product sales, revenues, costs and expenses; potential clinical and regulatory milestones, including data readouts and regulatory submissions, potential marketing approvals and commercial performance. If successful, the combination of TUKYSA plus KADCYLA has the potential to strengthen TUKYSA\u00e2\u0080\u0099s position in the second-line setting, particularly in patients with brain metastases and could provide an alternative important option in the third-line setting for those patients who would otherwise have received KADCYLA monotherapy. Yes, that\u00e2\u0080\u0099s a great question. Andy, thanks for the question. Hi, thanks for taking our question. Thanks for the question. Hi, thanks for taking our question. Thanks for the question. Thanks for the question. Yes, that\u00e2\u0080\u0099s a great question. Thanks for the question. Andy, thanks for the question."
}